Journal article
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
Abstract
BACKGROUND: Factor Xa plays a central role in the generation of thrombin, making it a novel target for treatment of arterial thrombosis. Fondaparinux is a synthetic factor Xa inhibitor that has been shown to be superior to standard therapies for the prevention of venous thrombosis. We performed a randomized trial to determine the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting.
METHODS AND RESULTS: …
Authors
Mehta SR; Steg PG; Granger CB; Bassand J-P; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJG; Natarajan MK
Journal
Circulation, Vol. 111, No. 11, pp. 1390–1397
Publisher
Wolters Kluwer
Publication Date
March 22, 2005
DOI
10.1161/01.cir.0000158485.70761.67
ISSN
0009-7322